Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xeris Biopharma Holdings (XERS) Revenue (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Revenue for 6 consecutive years, with $85.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 42.78% year-over-year to $85.8 million, compared with a TTM value of $291.8 million through Dec 2025, up 43.72%, and an annual FY2025 reading of $291.8 million, up 43.72% over the prior year.
  • Revenue was $85.8 million for Q4 2025 at Xeris Biopharma Holdings, up from $74.4 million in the prior quarter.
  • Across five years, Revenue topped out at $85.8 million in Q4 2025 and bottomed at $8.2 million in Q1 2021.
  • Average Revenue over 5 years is $40.9 million, with a median of $39.3 million recorded in 2023.
  • The sharpest move saw Revenue surged 184.15% in 2022, then increased 12.31% in 2024.
  • Year by year, Revenue stood at $21.7 million in 2021, then soared by 52.81% to $33.1 million in 2022, then surged by 33.93% to $44.4 million in 2023, then soared by 35.39% to $60.1 million in 2024, then skyrocketed by 42.78% to $85.8 million in 2025.
  • Business Quant data shows Revenue for XERS at $85.8 million in Q4 2025, $74.4 million in Q3 2025, and $71.5 million in Q2 2025.